Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The youngest child in India to survive ECMO after undergoing bone marrow transplant for a rare disease
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
Subscribe To Our Newsletter & Stay Updated
